(via NewsDirect)
The company successfully raised
DuMoulin-White detailed the unique approach, utilizing a drug-device combination involving a light-sensitive drug instilled into the bladder. This innovative method selectively targets cancer cells, minimizing damage to healthy cells, a departure from traditional pharmacological approaches.
Currently working on its pre-Breakthrough Therapy Designation (BTD) with the FDA,
Dumoulin-White highlighted the company's focus on non-dilutive financing, potential partnerships, and completing the primary study treatment for around 100 patients by the end of 2024. Successful completion could lead to an FDA decision, ideally by the end of 2026, potentially accelerated with priority review.
Contact Details
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source